MDA-MB-231: Discovery of a Novel Type of Extracellular Vesicle as a Potential Target for Cancer Immunotherapy
In the microscopic world of our bodies, cells are constantly engaged in complex and orderly activities. Communication between cells is like a precisely coordinated symphony of information transfer, essential for maintaining normal physiological function. Extracellular vesicles (EVs), as crucial messengers in intercellular communication, play indispensable roles in numerous physiological and pathological processes. They are involved in immune regulation, tissue repair, tumor development, and many other processes, closely linked to our health. However, our understanding of EVs is still far from complete, and this microcosm holds many undiscovered secrets.Recently, a study titled "Blebbisomes are large, organelle-rich extracellular vesicles with cell-like properties" published in Nature Cell Biology has discovered a novel type of extracellular vesicle—termed 'blebbisomes' . This finding opens a completely new avenue for research into intercellular communication.
Morphology and Structure of Blebbisomes
While deeply exploring vesicles and nanoparticles released by cells, researchers identified a distinct population of large extracellular vesicles, named "blebbisomes" due to their prominent blebbing membrane dynamics.
Blebbisomes are colossal in size within the EV family, with an average diameter of 10 μm and reaching up to 20 μm, far exceeding other known EVs. High-resolution microscopy revealed that blebbisomes possess a unique membrane structure, with a dynamic, blebbing appearance on their surface. Their internal architecture is remarkably complex, containing various organelles including mitochondria, endoplasmic reticulum, Golgi apparatus, ribosomes, and lysosomes. The mitochondria are not only abundant but were confirmed via specific staining and functional assays to be fully functional, capable of providing sufficient energy for the activities of blebbisomes and maintaining their active state.
Figure 1: Blebbisomes form with functional mitochondria.
Bidirectional Transport Function
Functionally, blebbisomes exhibit a unique bidirectional transport capacity. By labeling purified small EVs and co-incubating them with blebbisomes, researchers used advanced imaging techniques to observe that blebbisomes can uptake these small EVs from the extracellular environment, achieving material absorption and accumulation.
Simultaneously, blebbisomes contain multivesicular endosome (MVE)-like structures and possess secretion-related proteins, suggesting they can also secrete exosomes and microvesicles. These secreted vesicles contain various bioactive molecules, enabling them to participate in intercellular material exchange and information transfer, playing critical roles in the extracellular environment.
Figure 3: Blebbisomes uptake extracellular vesicles.
Broad Cellular Origins
The production of blebbisomes is not restricted to specific cell types. Studying various cell types, researchers found that both normal human cells, such as colon fibroblasts and cardiomyocytes, and cancer cells, including breast cancer, colorectal cancer, and melanoma cells, are capable of releasing blebbisomes.
In vivo, after implanting melanoma cells into zebrafish embryos, microscopy revealed these cells release blebbisomes. Analysis of bone marrow extracted from normal mice also detected the presence of blebbisomes. This series of experiments strongly indicates that blebbisome formation is a universal cellular phenomenon, potentially playing a role in both normal physiological processes and disease pathogenesis.
Association with Tumor Immunity
Furthermore, the study discovered that cancer cell-derived blebbisomes are enriched with numerous immune evasion and inhibitory immune checkpoint proteins, including PD-L1, PD-L2, and B7-H3. Using techniques like immunoblotting, researchers not only confirmed the presence of these proteins but also performed quantitative analysis of their levels.
The results showed that in blebbisomes derived from MDA-MB-231 breast cancer cells, the levels of proteins such as PD-L2, VISTA, and HLA-E were significantly higher compared to corresponding large and small EVs. These proteins can inhibit the immune system's attack on tumor cells, helping them evade immune surveillance. For example, PD-L1 protein carried by tumor cell-derived blebbisomes can bind to receptors on the surface of T cells, inhibiting their activity and allowing tumor cells to evade T cell recognition and killing. This finding provides crucial new clues for understanding mechanisms of tumor immune evasion.
Figure 4: Blebbisome-like vesicles exist in vivo and contain immune checkpoint ligands.
Contact us to discuss your research needs. Our MDA-MB-231-Luc luciferase stable cell line provides consistent bioluminescence signal for your breast cancer therapy studies — request a quote now to get started.
Order now: MDA-MB-231 cell line, MDA-MB-231-Luc cell line, MDA-MB-231-Luc-GFP cell line
This research on blebbisomes greatly enriches our understanding of the EV family, points to a new direction for studying intercellular communication, and offers new potential targets for disease diagnosis and therapy.
As research on blebbisomes deepens, we can expect to better understand their detailed mechanisms in physiology and pathology, laying a solid theoretical foundation for developing novel therapeutic approaches. For instance, studying immune checkpoint proteins in cancer-derived blebbisomes may lead to completely new strategies and breakthroughs in cancer immunotherapy.
Admittedly, our understanding of blebbisomes is still in its early stages, and many unknowns remain. What are the specific mechanisms of blebbisomes in different diseases? Do different subtypes exist? How can their functions be precisely regulated? These questions require further in-depth investigation. Through the diligent efforts of researchers, our knowledge of blebbisomes will grow, and we are hopeful that these research findings can be translated into practical medical applications, bringing more hope to human health. We look forward to further breakthroughs in the field of extracellular vesicles, driving medical advancements to new heights and safeguarding life and health.
